NCT03986424 (MIND) is a Phase 3 clinical trial of Akatinol Memantine 20 mg in Vascular Dementia, sponsored by Merz Pharmaceuticals GmbH.

Who is sponsoring NCT03986424?

NCT03986424 is sponsored by Merz Pharmaceuticals GmbH.

What drugs are being tested in NCT03986424?

Interventions in NCT03986424: Akatinol Memantine 20 mg, Akatinol Memantine 10 mg.

What condition does NCT03986424 study?

NCT03986424 studies Vascular Dementia.

Is NCT03986424 still recruiting?

NCT03986424 is currently completed. Last updated 22 July 2022.

Last reviewed 2022-07-22 · How we verify

NCT03986424: MIND

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Local Study of Akatinol Memantine in VaD in Russia

Completed Phase 3 Last updated 22 July 2022

What this trial tests

Phase 3 trial testing Akatinol Memantine 20 mg in Vascular Dementia in 130 participants. Completed in 1 June 2022.

Timeline

23 January 2018

Primary endpoint
1 June 2022

1 June 2022

Quick facts

Lead sponsor	Merz Pharmaceuticals GmbH
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	130
Start date	23 January 2018
Primary completion	1 June 2022
Estimated completion	1 June 2022
Sites	4 locations across Russia

Drugs / interventions tested

Akatinol Memantine 20 mg — full drug profile →
Akatinol Memantine 10 mg — full drug profile →

Conditions studied

Vascular Dementia — all drugs for Vascular Dementia →

Sponsor

Merz Pharmaceuticals GmbH — full company profile →

Who can join

Adults 50 to 85, any sex, with Vascular Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study evaluates the clinical efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs. Akatinol Memantine 10 mg (double-doses) in patients suffering from moderate and moderately severe vascular dementia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Trials of New Drugs for Vascular Cognitive Impairment and Vascular Dementia.
Linh TTD, Hsieh YC, Huang LK, Hu CJ. · · 2022 · cited 39× · PMID 36232368 · DOI 10.3390/ijms231911067
Mechanisms of mitophagy and oxidative stress in cerebral ischemia-reperfusion, vascular dementia, and Alzheimer's disease.
Lyu Y, Meng Z, Hu Y, Jiang B, et al · · 2024 · cited 19× · PMID 39169952 · DOI 10.3389/fnmol.2024.1394932

Verify or expand the search:

Other recruiting trials for Vascular Dementia

Currently open trials in the same condition.

NCT07149038 — Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment · NA · recruiting
NCT06298474 — The BRAIN App (Phase 2 SBIR) · NA · recruiting
NCT06862557 — Pulsed Electromagnetic Field Treatment With Dementia Patients · NA · recruiting
NCT06416371 — Retinal Vessel Leakage in Cerebral Small Vessel Disease · recruiting
NCT07259499 — Predictors of Emergency Department Use in Frail Patients · recruiting

Other Merz Pharmaceuticals GmbH trials

Trials by the same sponsor.

NCT05585398 — A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Di · Phase 1 · completed
NCT04766723 — A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Ad · Phase 2 · completed
NCT03256942 — Evaluation of the Sensitivity of Merz Lips Fullness Assessment Scale Following Etermis 4® Treatment for Lips Volume Augm · NA · completed
NCT04210258 — Post-Market Clinical Follow-up Performance and Safety Study of Etermis 3 and 4 in the Face · completed
NCT02270736 — Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troubles · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03986424 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merz Pharmaceuticals GmbH
Last refreshed: 22 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03986424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing